123 related articles for article (PubMed ID: 10439315)
1. Mutation in the beta 2m gene is not a frequent event in head and neck squamous cell carcinomas.
Feenstra M; Rozemuller E; Duran K; Stuy I; van den Tweel J; Slootweg P; de Weger R; Tilanus M
Hum Immunol; 1999 Aug; 60(8):697-706. PubMed ID: 10439315
[TBL] [Abstract][Full Text] [Related]
2. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas.
Feenstra M; Veltkamp M; van Kuik J; Wiertsema S; Slootweg P; van den Tweel J; de Weger R; Tilanus M
Tissue Antigens; 1999 Sep; 54(3):235-45. PubMed ID: 10519360
[TBL] [Abstract][Full Text] [Related]
3. An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma.
Vora AR; Rodgers S; Parker AJ; Start R; Rees RC; Murray AK
Br J Cancer; 1997; 76(7):836-44. PubMed ID: 9328140
[TBL] [Abstract][Full Text] [Related]
4. Investigation of HLA class I downregulation in breast cancer by RT-PCR.
Palmisano GL; Pistillo MP; Capanni P; Pera C; Nicolò G; Salvi S; Perdelli L; Pasciucco G; Ferrara GB
Hum Immunol; 2001 Feb; 62(2):133-9. PubMed ID: 11182222
[TBL] [Abstract][Full Text] [Related]
5. Detection of a putative HLA-A*31012 processed (intronless) pseudogene in a laryngeal squamous cell carcinoma.
Feenstra M; Bakema J; Verdaasdonk M; Rozemuller E; van den Tweel J; Slootweg P; de Weger R; Tilanus M
Genes Chromosomes Cancer; 2000 Jan; 27(1):26-34. PubMed ID: 10564583
[TBL] [Abstract][Full Text] [Related]
6. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.
Meissner M; Reichert TE; Kunkel M; Gooding W; Whiteside TL; Ferrone S; Seliger B
Clin Cancer Res; 2005 Apr; 11(7):2552-60. PubMed ID: 15814633
[TBL] [Abstract][Full Text] [Related]
7. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis.
Bandoh N; Ogino T; Katayama A; Takahara M; Katada A; Hayashi T; Harabuchi Y
Oncol Rep; 2010 Apr; 23(4):933-9. PubMed ID: 20204276
[TBL] [Abstract][Full Text] [Related]
8. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.
Korkolopoulou P; Kaklamanis L; Pezzella F; Harris AL; Gatter KC
Br J Cancer; 1996 Jan; 73(2):148-53. PubMed ID: 8546899
[TBL] [Abstract][Full Text] [Related]
9. HLA antigen expression in routinely processed head and neck squamous cell carcinoma primary lesions of different sites.
Mattijssen V; De Mulder PH; Schalkwijk L; Manni JJ; Van 't Hof-Grootenboer B; Ruiter DJ
Int J Cancer Suppl; 1991; 6():95-100. PubMed ID: 2066187
[TBL] [Abstract][Full Text] [Related]
10. Loss of HLA heavy chain and beta 2-microglobulin in HLA negative tumours.
Cabrera T; Concha A; Ruiz-Cabello F; Garrido F
Scand J Immunol; 1991 Aug; 34(2):147-52. PubMed ID: 1866599
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite analysis of microdissected tumor cells and 6p high density microsatellite analysis in head and neck squamous cell carcinomas with down-regulated human leukocyte antigen class I expression.
Feenstra M; Verdaasdonk M; van der Zwan AW; de Weger R; Slootweg P; Tilanus M
Lab Invest; 2000 Mar; 80(3):405-14. PubMed ID: 10744076
[TBL] [Abstract][Full Text] [Related]
12. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors.
Cabrera CM; Jiménez P; Cabrera T; Esparza C; Ruiz-Cabello F; Garrido F
Tissue Antigens; 2003 Mar; 61(3):211-9. PubMed ID: 12694570
[TBL] [Abstract][Full Text] [Related]
13. Prominence of beta 2-microglobulin, class I heavy chain conformation, and tapasin in the interactions of class I heavy chain with calreticulin and the transporter associated with antigen processing.
Solheim JC; Harris MR; Kindle CS; Hansen TH
J Immunol; 1997 Mar; 158(5):2236-41. PubMed ID: 9036970
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of peptide and major histocompatibility complex class I/beta 2-microglobulin binding to the transporters associated with antigen processing (TAP1 and TAP2).
Androlewicz MJ; Ortmann B; van Endert PM; Spies T; Cresswell P
Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12716-20. PubMed ID: 7809108
[TBL] [Abstract][Full Text] [Related]
15. [Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in laryngeal squamous cell carcinoma].
Zeng Q; Wang XL; Xu ZG; Lü N; Zheng S; Zhao QZ; Tang PZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Mar; 47(3):234-40. PubMed ID: 22805026
[TBL] [Abstract][Full Text] [Related]
16. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression.
Keating PJ; Cromme FV; Duggan-Keen M; Snijders PJ; Walboomers JM; Hunter RD; Dyer PA; Stern PL
Br J Cancer; 1995 Aug; 72(2):405-11. PubMed ID: 7640226
[TBL] [Abstract][Full Text] [Related]
17. MUTYH-associated polyposis carcinomas frequently lose HLA class I expression - a common event amongst DNA-repair-deficient colorectal cancers.
de Miranda NF; Nielsen M; Pereira D; van Puijenbroek M; Vasen HF; Hes FJ; van Wezel T; Morreau H
J Pathol; 2009 Sep; 219(1):69-76. PubMed ID: 19462419
[TBL] [Abstract][Full Text] [Related]
18. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer.
Romero JM; Jiménez P; Cabrera T; Cózar JM; Pedrinaci S; Tallada M; Garrido F; Ruiz-Cabello F
Int J Cancer; 2005 Feb; 113(4):605-10. PubMed ID: 15455355
[TBL] [Abstract][Full Text] [Related]
19. Multiple mechanisms underlie HLA dysregulation in cervical cancer.
Brady CS; Bartholomew JS; Burt DJ; Duggan-Keen MF; Glenville S; Telford N; Little AM; Davidson JA; Jimenez P; Ruiz-Cabello F; Garrido F; Stern PL
Tissue Antigens; 2000 May; 55(5):401-11. PubMed ID: 10885560
[TBL] [Abstract][Full Text] [Related]
20. MHC class I expression and CD8+ T cell development in TAP1/beta 2-microglobulin double mutant mice.
Ljunggren HG; Van Kaer L; Sabatine MS; Auchincloss H; Tonegawa S; Ploegh HL
Int Immunol; 1995 Jun; 7(6):975-84. PubMed ID: 7577806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
